• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treating Patients With Inflammatory Bowel Disease During and After Cancer.

作者信息

Axelrad Jordan

机构信息

Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health Associate Professor of Medicine NYU Grossman School of Medicine New York, New York.

出版信息

Gastroenterol Hepatol (N Y). 2025 Jun;21(6):387-389.

PMID:40896756
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12397801/
Abstract
摘要

相似文献

1
Treating Patients With Inflammatory Bowel Disease During and After Cancer.癌症期间及之后对炎症性肠病患者的治疗。
Gastroenterol Hepatol (N Y). 2025 Jun;21(6):387-389.
2
Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH study.维多珠单抗治疗的炎症性肠病患者的医疗资源利用和生产损失：瑞典前瞻性多中心SVEAH研究的结果
Therap Adv Gastroenterol. 2025 Jul 17;18:17562848251352023. doi: 10.1177/17562848251352023. eCollection 2025.
3
Watch and Wait for rectal cancer in inflammatory bowel disease.观察和等待炎症性肠病中的直肠癌。
BMJ Case Rep. 2023 Jul 10;16(7):e252562. doi: 10.1136/bcr-2022-252562.
4
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.丹麦一项全国性基于人群的队列研究：抗肿瘤坏死因子-α 治疗与炎症性肠病、类风湿关节炎或银屑病且既往有癌症患者的复发性或新发原发性癌症。
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):276-284. doi: 10.1016/S2468-1253(19)30362-0. Epub 2019 Dec 10.
5
Management of biologics in pregnant, lactating patients with inflammatory bowel disease and the impact on neonatal vaccination: A systematic review of clinical practice guidelines and consensus statements.炎症性肠病孕妇及哺乳期患者生物制剂的管理及其对新生儿疫苗接种的影响：临床实践指南和共识声明的系统评价
J Clin Pharm Ther. 2022 Dec;47(12):1952-1965. doi: 10.1111/jcpt.13817. Epub 2022 Nov 30.
6
The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab.使用英夫利昔单抗成功治疗炎症性肠病时，肠道黏膜和粪便中的细菌总量会增加。
Microbiol Spectr. 2025 Aug 5;13(8):e0189424. doi: 10.1128/spectrum.01894-24. Epub 2025 Jul 7.
7
Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Jul 22. doi: 10.1111/apt.70296.
8
Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review.抗肿瘤坏死因子-α治疗在炎症性肠病女性怀孕期间可能不安全：更新的荟萃分析和系统评价。
BMC Pregnancy Childbirth. 2024 Apr 8;24(1):251. doi: 10.1186/s12884-024-06443-w.
9
Association between food diversity in the infant period and the risk of inflammatory bowel disease: a nationwide cohort study in South Korea.婴儿期食物多样性与炎症性肠病风险之间的关联：韩国一项全国性队列研究
J Crohns Colitis. 2025 Jul 3;19(7). doi: 10.1093/ecco-jcc/jjaf101.
10
Colorectal cancer risk of flat low-grade dysplasia in inflammatory bowel disease: a systematic review and proportion meta-analysis.炎症性肠病中扁平低级别发育异常的结直肠癌风险：一项系统评价和比例Meta分析
Surg Endosc. 2023 Jan;37(1):48-61. doi: 10.1007/s00464-022-09462-w. Epub 2022 Aug 3.

本文引用的文献

1
Safety of Immunosuppression in a Prospective Cohort of Inflammatory Bowel Disease Patients With a HIstoRy of CancEr: SAPPHIRE Registry.患有癌症病史的炎性肠病患者前瞻性队列中免疫抑制的安全性：蓝宝石注册研究
Clin Gastroenterol Hepatol. 2025 Apr;23(5):855-865.e5. doi: 10.1016/j.cgh.2024.05.006. Epub 2024 May 18.
2
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients With Malignancy: Commentary.AGA 临床实践更新：恶性肿瘤患者炎症性肠病的管理：评论。
Clin Gastroenterol Hepatol. 2024 Jul;22(7):1365-1372. doi: 10.1016/j.cgh.2024.03.032. Epub 2024 May 14.
3
Cancer in Inflammatory Bowel Disease.炎症性肠病相关癌症。
Gastroenterol Clin North Am. 2022 Sep;51(3):649-666. doi: 10.1016/j.gtc.2022.05.003. Epub 2022 Aug 30.
4
Ustekinumab and Vedolizumab Are Not Associated With Subsequent Cancer in IBD Patients with Prior Malignancy.乌司奴单抗和维得利珠单抗与先前患有恶性肿瘤的 IBD 患者的后续癌症无关。
Inflamm Bowel Dis. 2022 Dec 1;28(12):1826-1832. doi: 10.1093/ibd/izac035.
5
The Complex Interplay Between Inflammatory Bowel Disease and Malignancy.炎症性肠病与恶性肿瘤之间的复杂相互作用
Curr Gastroenterol Rep. 2020 Feb 13;22(3):13. doi: 10.1007/s11894-020-0747-9.
6
Cancers complicating inflammatory bowel disease.炎症性肠病并发的癌症。
N Engl J Med. 2015 Apr 9;372(15):1441-52. doi: 10.1056/NEJMra1403718.
7
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies.炎症性肠病患者结直肠癌发病风险降低：基于人群队列研究的更新荟萃分析。
Inflamm Bowel Dis. 2013 Mar-Apr;19(4):789-99. doi: 10.1097/MIB.0b013e31828029c0.